Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
4.260
-0.390 (-8.39%)
Oct 25, 2024, 4:00 PM EDT - Market closed
Climb Bio Employees
As of December 31, 2023, Climb Bio had 11 total employees, including 9 full-time and 2 part-time employees. The number of employees decreased by 32 or -74.42% compared to the previous year.
Employees
11
Change (1Y)
-32
Growth (1Y)
-74.42%
Revenue / Employee
n/a
Profits / Employee
-$5,835,909
Market Cap
285.68M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 11 | -32 | -74.42% |
Dec 31, 2022 | 43 | 12 | 38.71% |
Dec 31, 2021 | 31 | - | - |
Related Stocks
Company Name | Employees |
---|---|
OraSure Technologies | 638 |
Spok Holdings | 384 |
Kamada | 378 |
AC Immune | 161 |
Monte Rosa Therapeutics | 133 |
Inozyme Pharma | 59 |
Design Therapeutics | 58 |
Jasper Therapeutics | 45 |
CLYM News
- 12 days ago - Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event - GlobeNewsWire
- 16 days ago - Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire
- 23 days ago - Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - GlobeNewsWire
- 24 days ago - Climb Bio to Host Virtual Investor Event on October 15, 2024 - GlobeNewsWire
- 25 days ago - Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - GlobeNewsWire
- 6 weeks ago - Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewsWire
- 2 months ago - Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewsWire
- 2 months ago - Eliem Therapeutics Reports Second Quarter Financial Results - GlobeNewsWire